Investor Relations

Stock Quote - Ticker Tape

 

Annual Meeting

  o Directions to CEL-SCI's Annual Meeting  
       

SEC Filings

  o View CEL-SCI's SEC Filings  
       

CEL-SCI Presentations & Interviews

  February 23, 2016
Interview with Geert Kersten at the Source Capital 2016 Disruptive Growth & Healthcare Conference

 
  February 17, 2016
NEW CLIP Geert Kersten as a featured guest on Fox Business' Making Money with Charles Payne

 
  January 2016
NEW INTERVIEW Interview with Dr. Eyal Talor, Chief Scientific Officer

 
  January 2016
Geert Kersten at the Noble Financial Capital Markets' 12th Annual Investor Conference

 

Warrant Quote

  o NYSE MKT: CVM WS  

 

Press Releases

  o All Press Releases  
 
  AUGUST 23, 2016
NEW STORY CEL-SCI Announces $5 Million Registered Direct Offering
  AUGUST 10, 2016
NEW STORY CEL-SCI Corporation Reports Third Quarter Fiscal Year 2016 Financial Results
  AUGUST 1, 2016
NEW STORY CEL-SCI Reports Monthly Patient Enrollment in July for Its Phase 3 Head and Neck Cancer Trial
  JULY 11, 2016
NEW STORY CEL-SCI Granted European Patent for Multikine Cancer Immunotherapy in Combination with Radiation and/or Chemotherapy
  MAY 24, 2016
NEW STORY CEL-SCI Announces the Closing of Its $5 Million Registered Direct Offering
  MAY 10, 2016
NEW STORY CEL-SCI Corporation Reports Second Quarter Fiscal Year 2016 Financial Results
  MAY 2, 2016
NEW STORY CEL-SCI Reports Record Monthly Patient Enrollment in April for Its Phase 3 Head and Neck Cancer Trial
  JANUARY 8, 2016
NEW STORY CEL-SCI Corporation Summarizes Significant Accomplishments in 2015 and Positive Momentum For 2016
  JANUARY 5, 2016
NEW STORY CEL-SCI Reports Record Year for Patient Enrollment With 75% Increase in Its Global Phase 3 Head and Neck Cancer Trial
  DECEMBER 11, 2015
NEW STORY CEL-SCI Reports Fiscal 2015 Financial Results and Clinical & Corporate Developments
  OCTOBER 14, 2015
CEL-SCI to Receive Up to $5,000,000 in Litigation Funding to Support Its Arbitration Suit Against Former CRO
  OCTOBER 5, 2015
Ergomed Increases Its Co-Development Contribution Up To $12,000,000 In CEL-SCI's Phase 3 Head and Neck Cancer Trial

Investor Relations Contact

   

Gavin de Windt
Phone: +1 703-506-9460
E-mail: gdewindt@cel-sci.com